Literature DB >> 1981969

Antianaphylactic and antihistaminic activity of the non-steroidal anti-inflammatory compound nimesulide in guinea-pig.

F Berti1, G Rossoni, A Buschi, M Robuschi, L M Villa.   

Abstract

Nimesulide (4-nitro-2-phenoxymethane sulfonanilide, Aulin, Mesulid) is a non-steroidal anti-inflammatory compound which shows antihistaminic activity and inhibits the immune release of histamine. The antihistaminic activity of this compound is specific for H1-receptor and has been demonstrated on isolated strips of guinea-pig trachea and on histamine-induced multiphasic inotropic response in left atria of guinea pig electrically driven. The effect of nimesulide is of non competitive type and, at the concentration of 1 x 10(-5) mol/l, is nearly 2 time less potent than pyrilamine (mepyramine) at 1 x 10(-6) mol/l. Nimesulide (1.6 mumol/kg i.v.) inhibits both bronchoconstriction (69%) and TXB2 formation (93%) induced by histamine (0.05 mumol/kg i.v.) in anaesthetized guinea-pigs. In contrast indomethacin (1.6 mumol/kg i.v.) decreases the generation of TXB2 (89%) without affecting the enhancement in tracheal insufflation pressure induced by histamine. In actively sensitized guinea-pigs both nimesulide and indomethacin protect the animals from deadly anaphylactic crisis. The rise in tracheal pressure induced by the antigenic challenge is inhibited of 80% and 63% respectively by nimesulide and indomethacin (6.4 mumol/kg i.v.). At this dose the two compounds reduced of 90% approximately the immunological release of TXB2 in the circulation. The release of histamine, induced by the anaphylactic reaction caused in perfused lungs obtained from actively sensitized guinea-pigs, is lessened by nimesulide (EC50 = 3.06; fid. lim. 2.59-3.63 mumol/l) and potentiated by indomethacin (EC50 = 0.89; fid. lim. 0.67-1.17 mumol/l).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1981969

Source DB:  PubMed          Journal:  Arzneimittelforschung        ISSN: 0004-4172


  9 in total

Review 1.  The importance of COX-2 inhibition for aspirin induced asthma.

Authors:  A Bennett
Journal:  Thorax       Date:  2000-10       Impact factor: 9.139

Review 2.  Treatment of bronchospastic disorders in the 1990s. What does the future hold?

Authors:  P G Gianaris; J A Golish
Journal:  Drugs       Date:  1993-07       Impact factor: 9.546

Review 3.  The effect of nimesulide on prostanoid formation.

Authors:  E Magni
Journal:  Drugs       Date:  1993       Impact factor: 9.546

Review 4.  Nimesulide in the treatment of patients intolerant of aspirin and other NSAIDs.

Authors:  G E Senna; G Passalacqua; G Andri; A R Dama; M Albano; L Fregonese; L Andri
Journal:  Drug Saf       Date:  1996-02       Impact factor: 5.606

Review 5.  Recent contributions to knowledge of the mechanism of action of nimesulide.

Authors:  M Bevilacqua; E Magni
Journal:  Drugs       Date:  1993       Impact factor: 9.546

Review 6.  Efficacy and tolerability of nimesulide in asthmatic patients intolerant to aspirin.

Authors:  S Bianco; M Robuschi; G Petrigni; M Scuri; M G Pieroni; R M Refini; A Vaghi; P S Sestini
Journal:  Drugs       Date:  1993       Impact factor: 9.546

7.  New data concerning the antianaphylactic and antihistaminic activity of nimesulide.

Authors:  G Rossoni; F Berti; A Buschi; L M Villa; D D Bella
Journal:  Drugs       Date:  1993       Impact factor: 9.546

Review 8.  Clinical pharmacokinetics of nimesulide.

Authors:  A Bernareggi
Journal:  Clin Pharmacokinet       Date:  1998-10       Impact factor: 6.447

Review 9.  Nimesulide. An update of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy.

Authors:  R Davis; R N Brogden
Journal:  Drugs       Date:  1994-09       Impact factor: 9.546

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.